Lv1
60 积分 2024-12-04 加入
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
14天前
已完结
PT1.07.03 Adjuvant Osimertinib in IB-IIIB NSCLC with Uncommon EGFR Mutations (Admin): Mutation Profile and ctDNA Dynamics
29天前
已关闭
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1个月前
已完结
Combined stereotactic radiotherapy and immunotherapy improves survival in driver-gene-negative NSCLC patients with brain oligo-metastases: a multicenter real-world study
1个月前
已完结
Combined stereotactic radiotherapy and immunotherapy improves survival in driver-gene-negative NSCLC patients with brain oligo-metastases: a multicenter real-world study
1个月前
已完结
The safety and efficacy of anti-PD-1/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis
2个月前
已完结
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
3个月前
已完结
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ
3个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4个月前
已完结
皖公网安备34019202002308
